

## Full title

Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study

## Short Title

SARS-CoV-2 risk factors for mechanical ventilation

## Authors and affiliations

Jean Regina<sup>1</sup>, Matthaios Papadimitriou-Olivgeris<sup>1,2</sup>, Raphaël Burger<sup>1,3</sup>, Paraskevas Filippidis<sup>1</sup>, Jonathan Tschopp<sup>1</sup>, Florian Desgranges<sup>1</sup>, Benjamin Viala<sup>1</sup>, Eleftheria Kampouri<sup>1</sup>, Laurence Rochat<sup>1</sup>, David Haefliger<sup>1</sup>, Mhedi Belkoniene<sup>1,3</sup>, Carlos Fidalgo<sup>1,3</sup>, Antonios Kritikos<sup>1</sup>, Katia Jatou<sup>4</sup>, Laurence Senn<sup>2</sup>, Pierre-Alexandre Bart<sup>3</sup>, Jean-Luc Pagani<sup>5</sup>, Oriol Manuel<sup>1</sup>, Loïc Lhopitallier<sup>1</sup>

<sup>1</sup>Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

<sup>2</sup>Service of Hospital Preventive Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

<sup>3</sup>Service of Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

<sup>4</sup>Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

<sup>5</sup>Service of Intensive Care, Lausanne University Hospital and University of Lausanne,  
Lausanne, Switzerland

## Keywords

COVID-19; SARS-CoV-2; Switzerland; Mechanical Ventilation

## Contact

Corresponding author:

Loïc Lhopitallier, MD

Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne

Rue du Bugnon 46

Lausanne 1011, Switzerland

[loic.lhopitallier@chuv.ch](mailto:loic.lhopitallier@chuv.ch)

+41795560320

## Abstract

### Background

Coronavirus disease 2019 (COVID-19) is now a global pandemic with Europe and the USA at its epicenter. Little is known about risk factors for progression to severe disease in Europe. This study aims to describe the epidemiology of COVID-19 patients in a Swiss university hospital.

### Methods

This retrospective observational study included all adult patients hospitalized with a laboratory confirmed SARS-CoV-2 infection from March 1 to March 25, 2020. We extracted data from electronic health records. The primary outcome was the need to mechanical ventilation at day 14. We used multivariate logistic regression to identify risk factors for mechanical ventilation. Follow-up was of at least 14 days.

### Results

200 patients were included, of whom 37 (18.5%) needed mechanical ventilation at 14 days. The median time from symptoms onset to mechanical ventilation was 9.5 days (IQR 7.00, 12.75). Multivariable regression showed increased odds of mechanical ventilation in males (3.26, 1.21-9.8;  $p=0.025$ ), in patients who presented with a qSOFA score  $\geq 2$  (6.02, 2.09-18.82;  $p=0.001$ ), with bilateral infiltrate (5.75, 1.91-21.06;  $p=0.004$ ) or with a CRP of 40 mg/l or greater (4.73, 1.51-18.58;  $p=0.013$ ).

## Conclusions

This study gives some insight in the epidemiology and clinical course of patients admitted in a European tertiary hospital with SARS-CoV-2 infection. Male sex, high qSOFA score, CRP of 40 mg/l or greater and a bilateral radiological infiltrate could help clinicians identify patients at high risk for mechanical ventilation.

## Abbreviations

|              |   |
|--------------|---|
| CCI          | Charlson Comorbidity Index  |
| AKI          | Acute Kidney Injury   |
| ARDS         | Acute Respiratory Distress Syndrome                                 |
| LUH          | Lausanne University Hospital  |
| EHR          | Electronic Health Records   |
| CRP          | C-Reactive Protein  |
| PCT          | Procalcitonin   |
| MV           | Mechanical ventilation  |
| SOFA score   | Sequential Organ Failure Assessment score                           |
| qSOFA score  | quick SOFA score  |
| NEWS         | National Early Warning score  |
| CRB-65 score | Confusion/Respiratory rate/Blood pressure/age $\geq$ 65 years score |
| WHO          | World Health Organization   |

## 1 Introduction

2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan  
3 (China) in December 2019. WHO, in February 2020, named the resulting disease  
4 COronaVirus Induced Disease 2019 (COVID-19) [1]. There is a wide spectrum of severity  
5 ranging from asymptomatic presentation to severe pneumonia requiring ventilator support  
6 and death [2]. Since March 2020, the pace of SARS-CoV-2 spread around the globe increased  
7 as the epidemic evolved to a pandemic [3]. Europe and the USA are now at the epicenter of  
8 the pandemic and face increasing number of severe cases. By April 14 2020, Switzerland  
9 registered 25580 cases, 2936 hospitalisation and 885 deaths [4].

10 Several studies described epidemiological characteristics of COVID-19 patients in China  
11 [2,5,6]. To our knowledge, to the exception of a study including critically ill patients [7], none  
12 has so far described epidemiology, risk factors and clinical course of COVID-19 patients in a  
13 European setting.

14 We think that it is important to collect and analyse European data. The European population  
15 is older, with a likely different genetic background that may influence the evolution of  
16 disease and with different resources for responding to the outbreak. Furthermore, although  
17 many studies have modelled the risk of severe disease in Chinese patients, little is known  
18 about risk factors for progression to severe disease in Europe [8].

19 In the present study, we report the epidemiological and clinical characteristics of patients  
20 hospitalized for COVID-19 in a Swiss university hospital as well as risk factors for progressive  
21 respiratory failure requiring mechanical ventilation.

## 22 Methods

### 23 Study Setting

24 This study took place in Lausanne University Hospital (LUH), a one-thousand-bed tertiary  
25 university hospital in Lausanne, Switzerland. LUH serves as a primary-level community  
26 hospital for Lausanne (population circa 300'000 inhabitants) and as a referral hospital for  
27 Western Switzerland (population circa 1 – 1.5 million inhabitants). LUH increased its  
28 outbreak response capacity by setting up new intensive care units for the management of  
29 COVID-19 patients.

30

### 31 Study Design and Participants

32 This retrospective observational study analysed all adult patients consecutively hospitalized  
33 with a confirmed SARS-CoV-2 infection from March 1, 2020, to March 25, 2020. Patient's  
34 initial physicians used local guidelines to decide on admission (only patients with risk factors  
35 for severe disease or patients needing medical care were hospitalized). For all patients, we  
36 ensured of follow-up of up to at least 14 days, or up to discharge or death if they occurred  
37 first.

38

### 39 Data collection

40 LUH electronic health record (EHR) provided epidemiological, clinical, radiological and  
41 laboratory data.

42 Epidemiological data included age, sex, height, weight, and relevant comorbidities (including  
43 a Charlson Comorbidities Index (CCI)). We collected data on clinical presentation, SARS-CoV-

44 2 treatments, concomitant treatments, non-pharmacological interventions and clinical  
45 course within LUH.

46 We recorded radiological findings from reports of chest radiography or computed  
47 tomography (CT). We defined healthcare workers as professionals having direct contact with  
48 patients (nurses, physiotherapists, physicians, etc.) or patient samples.

49 Laboratory data included full blood count, D-dimers, creatinine, highly sensitive cardiac T-  
50 troponin, C-reactive protein (CRP), procalcitonin (PCT), ferritin, liver function tests, blood  
51 type and real-time PCR to detect SARS-CoV-2 [9].

52 We entered all data in an electronic clinical report form (eCRF) using the REDCap<sup>®</sup> platform  
53 (Research Electronic Data Capture v8.5.24, Vanderbilt University, Tennessee, USA) [10].

54 Fellows of the Infectious Diseases, Hospital Preventive Medicine and Internal Medicine  
55 Services at LUH entered the data and two of the authors (JR, MP) verified their integrity.

56

## 57 **Clinical management**

58 Treating physicians made all decisions regarding supportive care. Specialists in infectious  
59 diseases reviewed all SARS-CoV-2 treatment decisions according to the local  
60 recommendations. These included protease inhibitors (ritonavir-boosted lopinavir or  
61 atazanavir), hydroxychloroquine or remdesivir. Selected critically ill patients with high  
62 inflammatory markers (CRP, D-dimers, PCT and ferritin) received tocilizumab. The choice of  
63 treatment depended on drug availability, safety profile drug-drug interactions.

64 Treating physicians discussed *advance planning of care* and *do not resuscitate orders* with all  
65 patients. Limitations of care were decided upon admission according to the patient's values  
66 and goals and the treating physician's appreciation. We categorized these limitations into



67 two levels: 1) no limitation; 2) limitation to the best supportive care provided in non-  
68 monitored wards or intermediate care units but without mechanical ventilation (MV).

69

## 70 Definition

71 We defined a confirmed SARS-CoV-2 infection as a positive test for SARS-CoV-2 using real-  
72 time polymerase chain reaction (RT-PCR) technology in any respiratory sample .

73 We classified infection as nosocomial if the onset of symptoms started more than 96 hours  
74 after admission for another indication.

75 We defined obesity either as a body mass index (BMI) of 30 kg/m<sup>2</sup> or higher, or, when  
76 missing anthropometric data, a medical diagnosis of obesity.

77 We used the Berlin definition for Acute Respiratory Distress Syndrome (ARDS) [11]. We  
78 defined *shock* as refractory hypotension requiring infusion of vasopressors. Acute kidney  
79 injury (AKI) was identified and classified according to the 2012 Kidney Disease Improving  
80 Global Outcome guidelines [12]. We defined liver injury as a 3-fold or greater increase in  
81 transaminase levels.

82 We calculated quick Sequential Organ Failure Assessment (qSOFA) score,  
83 Confusion/Respiratory rate/Blood pressure/age $\geq$ 65 years (CRB-65) score and National  
84 Early Warning Score (NEWS) were assessed according to their original descriptions [13–15].

85 We defined MV as invasive respiratory support through a laryngeal or a tracheostomy tube

86

## 87 Outcome

88 The primary outcome was the use of MV for respiratory failure attributed to SARS-CoV-2  
89 pneumonia, within 14 days after admission.

90

## 91 Statistics

92 The number of cases diagnosed during the study period defined the sample size. Statistical  
93 analyses were performed using R software v3.6.2 (R Foundation for Statistical Computing;  
94 [www.r-project.org](http://www.r-project.org)). Categorical variables were presented as numbers (percentages),  
95 normally distributed continuous variables were presented as mean  $\pm$  standard deviation (SD)  
96 and continuous variables with a skewed distribution were presented as median  
97 [interquartile range (IQR)].

98 For the descriptive analysis, we analysed proportions of categorical variables using chi-  
99 square goodness of fit test; we used Student t-test for normally distributed variables or  
100 Mann-Whitney-Wilcoxon test for continuous variables with a skewed distribution.

101 We used a general linear model based on univariate and multivariate logistic regression to  
102 calculate odds ratio for MV. We excluded from the analysis, patients whose care was limited  
103 to the best supportive care and patients already mechanically ventilated on admission. To  
104 avoid bias resulting from treatment indication, we did not include SARS-CoV-2 specific  
105 treatments as variables in the model.

106 To select predictive variables included in the multivariable analysis model, we first identified  
107 clinically relevant variables from the univariate analysis for which the p-value was less than  
108 0.2. To avoid overfitting, the final multivariate model used only four variables chosen by a  
109 backward stepwise approach.

110 For the inflammatory biomarkers, we converted continuous variables to categorical variables  
111 using cut-off values previously identified in the literature [6,16,17].

112 We did not impute any values for missing data.

113

114

## 115 Ethics

116 This project was conducted in accordance with the Declaration of Helsinki, the principles of  
117 Good Clinical Practice and the Swiss Human Research Act (HRA). The project received  
118 approval from the Ethics Committee of canton Vaud, Switzerland (2020-00657) that waived  
119 the need for informed consent. All data were anonymized before analysis.

120

121

## 122 Results

### 123 Epidemiological characteristics

124 Overall, 200 patients with confirmed SARS-CoV-2 infection were hospitalized at LUH during  
125 the study period. In 54 (27.0%), care was agreed to be limited to best supportive care on  
126 admission, these patients were older and with more comorbidities (Table 1).

127 Median patient age was 70.0 years [IQR 55.0-81.0], ranging from 20.0 to 96.0 years. Eighty-  
128 three (43.0 %) of all inpatients were aged 65.0 years or younger. Median BMI was 26.02 [IQR  
129 22.5-30.71]. Overall, 33 (16.5%) patients acquired nosocomial SARS-CoV-2 infection.

130

131 **Table 1. Comparison of patients with and without limitation of care**

|                           | No limitation of care | Limitation of care   | P Value |
|---------------------------|-----------------------|----------------------|---------|
| n                         | 146                   | 54                   |         |
| Age, years (median [IQR]) | 62.50 [52.00, 74.00]  | 83.50 [80.00, 88.00] | <0.001  |
| Age group, years (n, %)   |                       |                      | <0.001  |
| 18-30                     | 7 (4.8)               | 1 (1.9)              |         |
| 31-50                     | 28 (19.2)             | 0 (0.0)              |         |
| 51-65                     | 47 (32.2)             | 3 (5.6)              |         |
| 65-80                     | 48 (32.9)             | 11 (20.4)            |         |

|   |                   |                   |        |
|---|-------------------|-------------------|--------|
| >80                                       | 16 (11.0)         | 39 (72.2)         |        |
| Charlson Comorbidity Index (median [IQR]) | 3.00 [1.00, 5.00] | 7.00 [5.00, 9.00] | <0.001 |
| Dementia (n, %)                           | 5 (3.4)           | 21 (38.9)         | <0.001 |
| Cancer (n, %)                             | 16 (11.0)         | 10 (18.5)         | 0.24   |

132

133

134 One hundred and sixty (80.8 %) patients had at least one comorbidity, with a median  
 135 Charlson Comorbidity Index of 4.0 [IQR 2.0-6.0]. Table 2 summarizes the characteristics of  
 136 this population whose most frequent comorbidities were hypertension (43.5%), obesity  
 137 (27.0%), diabetes (21.5%), coronary artery disease (17.5%) and chronic kidney disease  
 138 (14.0%).

139

140 Fifty-one (26.2 %) patients were treated with angiotensin-converting enzyme inhibitors  
 141 (ACEI) or angiotensin II receptor blockers (ARBs). Fourteen (7.0 %) were treated with  
 142 immunosuppressive drugs of which six (3.0 %) patients were transplant recipients (5 solid-  
 143 organ and 1 haematopoietic stem-cell transplantation). Twenty-six (13.0%) patients had an  
 144 active malignancy at the time of admission.

145

146 **Table 2. Demographics, clinical, laboratory and radiographic findings of patients on**  
 147 **admission**

|                           | Overall              | No mechanical ventilation | Mechanical ventilation | P Values |
|---------------------------|----------------------|---------------------------|------------------------|----------|
| n                         | 200                  | 163                       | 37                     |          |
| Male sex (n, %)           | 120 (60.0)           | 91 (55.8)                 | 29 (78.4)              | 0.019    |
| Age, years (median [IQR]) | 70.00 [55.00, 81.00] | 71.00 [55.00, 82.00]      | 66.00 [57.00, 79.00]   | 0.337    |
| Age group, years (n, %)   |                      |                           |                        | 0.231    |
| 18-30                     | 8 (4.0)              | 8 (4.9)                   | 0 (0.0)                |          |

|  |                      |                      |                      |       |
|--|----------------------|----------------------|----------------------|-------|
| 31-50  | 28 (14.0)            | 21 (12.9)            | 7 (18.9)             |       |
| 51-65  | 50 (25.0)            | 39 (23.9)            | 11 (29.7)            |       |
| 65-80  | 59 (29.5)            | 46 (28.2)            | 13 (35.1)            |       |
| >80  | 55 (27.5)            | 49 (30.1)            | 6 (16.2)             |       |
| Overweight (BMI>25 kg/m <sup>2</sup> ) (n, %)      | 102 (51.0)           | 75 (46.0)            | 27 (73.0)            | 0.005 |
| Obesity (BMI>30 kg/m <sup>2</sup> ) (n, %)         | 54 (27.0)            | 38 (23.3)            | 16 (43.2)            | 0.024 |
| Body mass index, kg/m <sup>2</sup> (median [IQR])  | 26.02 [22.50, 30.71] | 25.30 [21.85, 30.18] | 26.99 [24.43, 30.79] | 0.107 |
| Active smoking (n, %)                              | 9 (4.5)              | 9 (5.6)              | 0 (0.0)              | 0.301 |
| Pregnancy (n, %)                                   | 6 (7.5)              | 5 (6.9)              | 1 (12.5)             | 1     |
| Healthcare worker (n, %)                           | 7 (3.5)              | 4 (2.5)              | 3 (8.1)              | 0.236 |
| Comorbidity (n, %)                                 | 160 (80.8)           | 134 (83.2)           | 26 (70.3)            | 0.116 |
| Hypertension (n, %)                                | 87 (43.5)            | 72 (44.2)            | 15 (40.5)            | 0.827 |
| Atrial fibrillation (n, %)                         | 19 (9.5)             | 17 (10.4)            | 2 (5.4)              | 0.528 |
| Coronary artery disease (n, %)                     | 35 (17.5)            | 29 (17.8)            | 6 (16.2)             | 1     |
| Stroke (n, %)                                      | 21 (10.5)            | 19 (11.7)            | 2 (5.4)              | 0.411 |
| Chronic kidney disease (n, %)                      | 28 (14.0)            | 26 (16.0)            | 2 (5.4)              | 0.16  |
| Chronic obstructive pulmonary disease (n, %)       | 16 (8.0)             | 12 (7.4)             | 4 (10.8)             | 0.717 |
| Asthma (n, %)                                      | 8 (4.0)              | 7 (4.3)              | 1 (2.7)              | 1     |
| Diabetes (n, %)                                    | 43 (21.5)            | 35 (21.5)            | 8 (21.6)             | 1     |
| Cirrhosis (n, %)                                   | 6 (3.0)              | 6 (3.7)              | 0 (0.0)              | 0.515 |
| Charlson Comorbidity Index (median [IQR])          | 4.00 [2.00, 6.00]    | 4.00 [2.00, 7.00]    | 4.00 [1.00, 5.00]    | 0.141 |
| Transplantation (n, %)                             | 6 (3.0)              | 6 (3.7)              | 0 (0.0)              | 0.515 |
| Hematopoietic stem cell transplantation (n, %)     | 1 (0.5)              | 1 (0.6)              | 0 (0.0)              | 1     |
| Solid organ transplantation (n, %)                 | 5 (2.5)              | 5 (3.1)              | 0 (0.0)              | 0.62  |
| Cancer (n, %)                                      | 26 (13.0)            | 23 (14.1)            | 3 (8.1)              | 0.478 |
| HIV infection (n, %)                               | 3 (1.5)              | 2 (1.2)              | 1 (2.7)              | 1     |
| Immunosuppressive drugs (n, %)                     | 14 (7.0)             | 14 (8.6)             | 0 (0.0)              | 0.136 |
| ACE inhibitors or ARB II (n, %)                    | 51 (26.2)            | 40 (25.0)            | 11 (31.4)            | 0.568 |
| NSAIDs (n, %)                                      | 3 (1.5)              | 3 (1.9)              | 0 (0.0)              | 0.936 |
| Duration of symptoms before test, days (mean (SD)) | 6.10 (4.29)          | 5.80 (4.34)          | 7.38 (3.86)          | 0.043 |
| Fever (n, %)                                       | 131 (65.5)           | 104 (63.8)           | 27 (73.0)            | 0.386 |
| Fatigue (n, %)                                     | 99 (49.5)            | 81 (49.7)            | 18 (48.6)            | 1     |
| Cough (n, %)                                       | 124 (62.0)           | 95 (58.3)            | 29 (78.4)            | 0.037 |
| Anosmia/Dysgeusia (n, %)                           | 7 (3.5)              | 6 (3.7)              | 1 (2.7)              | 1     |

|   |                         |                         |                        |         |
|---|-------------------------|-------------------------|------------------------|---------|
| Dyspnea (n, %)  | 98 (49.0)               | 69 (42.3)               | 29 (78.4)              | <0.001  |
| Arthralgia/Myalgia (n, %)                                     | 40 (20.0)               | 30 (18.4)               | 10 (27.0)              | 0.339   |
| Nausea/Vomitting (n, %)                                       | 37 (18.5)               | 33 (20.2)               | 4 (10.8)               | 0.271   |
| Diarrhea (n, %)   | 42 (21.0)               | 37 (22.7)               | 5 (13.5)               | 0.31    |
| Loss of consciousness (n, %)                                  | 20 (10.0)               | 16 (9.8)                | 4 (10.8)               | 1       |
| Confusion (n, %)  | 17 (8.5)                | 13 (8.0)                | 4 (10.8)               | 0.817   |
| Temperature (median [IQR])                                    | 38.20 [37.60, 38.73]    | 38.15 [37.40, 38.62]    | 38.70 [37.98, 39.12]   | 0.004   |
| Systolic blood pressure (median [IQR])                        | 118.00 [105.00, 128.00] | 119.00 [109.00, 130.00] | 110.00 [97.00, 125.00] | 0.023   |
| Heart rate (median [IQR])                                     | 93.00 [82.00, 104.00]   | 92.00 [82.00, 102.25]   | 94.50 [88.00, 115.25]  | 0.035   |
| Respiratory rate (median [IQR])                               | 24.00 [20.00, 30.00]    | 23.00 [19.50, 28.00]    | 31.00 [28.00, 35.00]   | <0.001  |
| Glasgow Coma Scale = 15 points (n, %)                         | 180 (90.0)              | 148 (90.8)              | 32 (86.5)              | 0.653   |
| FiO <sub>2</sub> , percent (median [IQR])                     | 28.00 [21.00, 40.00]    | 26.00 [21.00, 30.00]    | 44.50 [28.50, 71.25]   | <0.001  |
| Nosocomial SARS-CoV-2 infection (n, %)                        | 26 (13.1)               | 26 (16.0)               | 0 (0.0)                | 0.019   |
| Co-infection on admission (n, %)                              | 17 (8.5)                | 9 (5.5)                 | 8 (21.6)               | 0.004   |
| Any imaging (n, %)  | 182 (93.3)              | 145 (90.6)              | 37 (100.0)             | 0.150   |
| Chest X-ray (n, %)  | 180/182 (98.9)          | 143/145 (96.6)          | 37/37 (100.0)          | 0.108   |
| Lung scan (n, %)  | 17/182 (9.3)            | 11/145 (7.6)            | 6/37 (16.2)            | 0.122   |
| Radiological infiltrate (n, %)                                | 126/182 (69.2)          | 91/145 (62.8)           | 35/37 (94.6)           | <0.001  |
| Bilateral infiltrate (n, %)                                   | 97/182 (53.3)           | 65/145 (44.8)           | 32/37 (86.5)           | <0.001  |
| CRB-65 score  |                         |                         |                        | 0.026*  |
| 0-1 (n, %)  | 122/190 (64.2)          | 105/153 (68.6)          | 17/37 (45.9)           |         |
| 2 (n, %)  | 45/190 (23.7)           | 33/153 (21.6)           | 12/37 (32.4)           |         |
| 3-5 (n, %)  | 23/190 (12.1)           | 15/153 (9.8)            | 8/37 (21.6)            |         |
| qSOFA score   |                         |                         |                        | <0.001* |
| 0 (n, %)  | 68/196 (34.7)           | 65/159 (40.9)           | 3/37 (8.1)             |         |
| 1 (n, %)  | 94/196 (48.0)           | 74/159 (46.5)           | 20/37 (54.1)           |         |
| 2 (n, %)  | 28/196 (14.3)           | 17/159 (10.7)           | 11/37 (29.7)           |         |
| 3 (n, %)  | 6/196 (3.1)             | 3/159 (1.9)             | 3/37 (8.1)             |         |
| NEWS score  |                         |                         |                        | <0.001* |
| 0 (n, %)  | 10/191 (5.2)            | 10/159 (6.3)            | 0/32 (0.0)             |         |
| 1-4 (n, %)  | 59/191 (30.9)           | 57/159 (35.8)           | 2/32 (6.2)             |         |
| 5-6 (n, %)  | 44/191 (23.0)           | 40/159 (25.2)           | 4/32 (12.5)            |         |
| 7 or more (n, %)  | 78/191 (40.8)           | 52/159 (32.7)           | 26/32 (81.2)           |         |
| White blood cell count, x10 <sup>9</sup> per L (median [IQR]) | 5.60 [4.40, 7.23]       | 5.30 [4.30, 6.80]       | 6.50 [5.10, 10.50]     | 0.003   |

|  |                          |                          |                           |        |
|--|--------------------------|--------------------------|---------------------------|--------|
| Lymphocytes count, x10 <sup>9</sup> per L (median [IQR]) | 0.80 [0.60, 1.21]        | 0.80 [0.57, 1.21]        | 0.86 [0.63, 1.15]         | 0.75   |
| Platelets count, x10 <sup>9</sup> per L (median [IQR])   | 202.00 [158.00, 257.00]  | 206.00 [161.50, 263.50]  | 185.00 [141.00, 237.00]   | 0.061  |
| D-dimers, ng/mL (median [IQR])                           | 966.00 [559.00, 2020.00] | 908.00 [513.50, 1961.00] | 1173.00 [729.75, 2455.50] | 0.062  |
| Creatinine, µmol/L (median [IQR])                        | 89.00 [71.50, 115.00]    | 88.50 [70.00, 112.75]    | 97.00 [82.00, 127.00]     | 0.102  |
| AKIN classification (n, %)                               |                          |                          |                           | 0.001* |
| 0  | 152 (76.0)               | 133 (81.6)               | 19 (51.4)                 |        |
| 1  | 41 (20.5)                | 133 (81.6)               | 14 (37.8)                 |        |
| 2  | 4 (2.0)                  | 2 (1.2)                  | 2 (5.4)                   |        |
| 3  | 3 (1.5)                  | 1 (0.6)                  | 2 (5.4)                   |        |
| CRP, mg/L (median [IQR])                                 | 48.00 [19.00, 103.50]    | 41.00 [15.00, 85.00]     | 132.00 [57.00, 198.00]    | <0.001 |
| PCT, µg/L (median [IQR])                                 | 0.14 [0.08, 0.27]        | 0.11 [0.08, 0.23]        | 0.21 [0.15, 0.52]         | <0.001 |
| Serum ferritin, µg/L (median [IQR])                      | 696.00 [305.00, 1546.00] | 628.50 [277.00, 1252.25] | 1546.00 [791.00, 2255.00] | 0.001  |
| High-sensitive cardiac troponin T, ng/L (median [IQR])   | 15.00 [6.50, 32.00]      | 15.00 [6.00, 32.00]      | 14.50 [7.75, 29.75]       | 0.836  |
| AST, U/L (median [IQR])                                  | 43.50 [33.00, 65.75]     | 42.00 [32.00, 58.00]     | 66.00 [37.00, 89.00]      | 0.005  |
| ALT, U/L (median [IQR])                                  | 30.00 [19.00, 54.00]     | 28.00 [19.00, 46.50]     | 40.00 [22.00, 75.00]      | 0.028  |
| Total bilirubin, µmol/L (median [IQR])                   | 8.00 [6.00, 12.00]       | 8.00 [5.00, 11.00]       | 10.00 [6.00, 14.00]       | 0.1    |
| ABO group done (n, %)                                    | 119 (59.5)               | 86 (52.8)                | 33 (89.2)                 | <0.001 |
| ABO group (n, %)   |                          |                          |                           | 0.449* |
| A  | 49/119 (41.2)            | 39/86 (45.3)             | 10/33 (30.3)              |        |
| B  | 16/119 (13.4)            | 10/86 (11.6)             | 6/33 (18.2)               |        |
| AB   | 5/119 (4.2)              | 3/86 (3.5)               | 2/33 (6.1)                |        |
| O  | 49/119 (41.2)            | 34/86 (39.5)             | 15/33 (45.5)              |        |

148

149 Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; ACE, angiotensin

150 converting enzyme; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-

151 inflammatory drugs; CRB-65 score, Confusion/Respiratory rate/Blood pressure/age<sub>≥65</sub>

152 years score; qSOFA score, quick Sequential Organ Failure Assessment score; NEWS, National

153 Early Warning Score; AKIN, Acute Kidney Injury Network; CRP, C-reactive protein; PCT,  
154 procalcitonin ; AST, aspartate transaminase; ALT, alanine transaminase.

155 \* $\chi^2$  test comparing all subcategories.

156

## 157 Clinical characteristics on admission

158 The mean duration of symptoms preceding admission (or first positive SARS-CoV-2 test for  
159 nosocomial cases) was six days (SD 4.29). The most frequent symptoms at the time of testing  
160 were fever in 131 patients (65.5%), cough in 124 (62.0%), fatigue in 99 (49.5%) and dyspnoea  
161 in 98 (49.0%).

162 Table 2 describes vital signs, qSOFA score, NEWS and CRB-65 scores on admission.

163

## 164 Laboratory values and radiology

165 Table 2 describes the median value of commonly measured inflammatory parameters (white  
166 blood cell count, CRP, procalcitonin, D-dimers and ferritin).

167 Overall, 182 patients (93.3%) had at least one radiological exam, 126/182 of them (69.2%)  
168 presented new lung infiltrates which were bilateral for 97/126 (77.0%) of them.

169

## 170 Treatments

171 118 (59.0%) of all patients received SARS-CoV-2 treatment (table 3). The most frequently  
172 prescribed medication were protease inhibitors in 103 patients (51.5%), hydroxychloroquine  
173 in 83 patients (41.5%) and remdesivir in 17 patients (8.5%). Seventeen (8.5%) patients  
174 received tocilizumab in adjunction to another SARS-CoV-2 treatment. Seventy-seven  
175 patients (38.5%) received two or more concomitant SARS-CoV-2 treatments. Seventy  
176 (35.0%) patients received antibiotics. One hundred and thirty-seven (68.5%) patients



177 required supplementary oxygen during the follow-up period.

178

179 **Table 3. Treatments received by patients during the follow-up period**

|                                 | <b>Overall</b> | <b>No mechanical ventilation</b> | <b>Mechanical ventilation</b> |
|---------------------------------|----------------|----------------------------------|-------------------------------|
| n                               | 200            | 163                              | 37                            |
| Any SARS-CoV-2 treatment (n, %) | 118 (59.0)     | 83 (50.9)                        | 35 (94.6)                     |
| Protease inhibitor (n, %)       | 103 (51.5)     | 71 (43.6)                        | 32 (86.5)                     |
| Hydroxychloroquine (n, %)       | 83 (41.5)      | 57 (35.0)                        | 26 (70.3)                     |
| Remdesivir (n, %)               | 17 (8.5)       | 0 (0.0)                          | 17 (45.9)                     |
| Tocilizumab (n, %)              | 17 (8.5)       | 3 (1.8)                          | 14 (37.8)                     |
| Any antibiotic treatment (n, %) | 70 (35.0)      | 38 (23.3)                        | 32 (86.5)                     |

180

181

182 **Clinical course**

183 Table 4 summarizes patient's clinical course. At the end of the follow-up, 39 (19.5%) patients  
 184 were still hospitalized, 101 (50.5%) patients were discharged, 21 (10.5%) patients were  
 185 transferred to a rehabilitation centre and 14 (7.0%) to another acute care hospital. Twenty-  
 186 five (12.5%) patients died during hospitalization.

187 Overall, 38 (19.0%) patients required mechanical ventilation, 37 (97.4%) of them before the  
 188 14<sup>th</sup> day and after a median of 2 days since admission (IQR 0.00 - 3.00). Median time from  
 189 symptom onset to mechanical ventilation was 9.5 days (IQR 7.00 - 12.75]. Regarding patients  
 190 requiring MV, 26 (68.4%) had a least one session of prone positioning, 24 (63.2%) received a  
 191 vasopressor, 11 (28.9%) were eventually weaned from ventilator support and 11 (28.9%)  
 192 died. The median duration of MV was 6 days (IQR 5.00 - 11.00). Twenty-two of the 38  
 193 patients (57.9%) requiring MW were admitted to new dedicated COVID-19 ICUs.

194

195 **Table 4. Clinical course**

|   | Overall             |
|---|---------------------|
| n   | 200                 |
| Time from hospitalization to oxygen need, days* (median [IQR])                        | 0.00 [0.00, 1.00]   |
| Time from symptoms onset to mechanical ventilation, days (median [IQR])               | 9.50 [7.00, 12.75]  |
| Time from hospitalization to mechanical ventilation, days* (median [IQR])             | 2.00 [0.00, 3.00]   |
| Duration of mechanical ventilation of extubated patients, days (median [IQR])         | 6.00 [5.00, 11.00]  |
| Outcome   |                     |
| Still Hospitalized (n, %)   | 39 (19.5)           |
| Discharge at home (n, %)  | 101 (50.5)          |
| Time from hospitalization to home discharge, days* (median [IQR])                     | 6.00 [4.00, 9.00]   |
| Readaptation (n, %)   | 21 (10.5)           |
| Time from hospitalization to readaptation discharge, days* (median [IQR])             | 12.00 [8.00, 16.75] |
| Transfer at other acute care hospital (n, %)  | 14 (7.0)            |
| Time from hospitalization to other acute care hospital transfer, days* (median [IQR]) | 6.00 [5.00, 9.00]   |
| Death (n, %)  | 25 (12.5)           |
| Time from hospitalization to death, days* (median [IQR])                              | 8.00 [4.00, 10.00]  |

196

197

198 **Complications**

199 Table 5 describes complications during follow-up. The most frequent complications were  
 200 ARDS ( $n = 44$ , 22.0%), acute confusional state ( $n = 30$ , 15.0 %), acute kidney injury ( $n=30$ ,  
 201 15.0%), hospital-acquired pneumonia (HAP) ( $n = 26$ , 13.0%) and arrhythmia ( $n = 21$ , 10.5%) of  
 202 patients.

203

204 **Table 5. Complications during the follow-up period**

|                                    | Overall  | No mechanical ventilation | Mechanical ventilation | P Values |
|------------------------------------|----------|---------------------------|------------------------|----------|
| n                                  | 200      | 164                       | 36                     |          |
| Asthma or COPD exacerbation (n, %) | 4 (2.0)  | 4 (2.4)                   | 0 (0.0)                | 0.772    |
| Community acquired                 | 11 (5.5) | 5 (3.0)                   | 6 (16.7)               | 0.004    |

|  |           |           |           |        |
|--|-----------|-----------|-----------|--------|
| pneumonia (n, %)                           |           |           |           |        |
| Hospital acquired pneumonia (n, %)         | 26 (13.0) | 10 (6.1)  | 16 (44.4) | <0.001 |
| Acute respiratory distress syndrome (n, %) | 44 (22.0) | 10 (6.1)  | 34 (94.4) | <0.001 |
| Pneumothorax (n, %)                        | 3 (1.5)   | 1 (0.6)   | 2 (5.6)   | 0.146  |
| Pulmonary embolism (n, %)                  | 6 (3.0)   | 4 (2.4)   | 2 (5.6)   | 0.65   |
| Other thromboembolic event (n, %)          | 6 (3.0)   | 3 (1.8)   | 3 (8.3)   | 0.126  |
| Acute confusional state (n, %)             | 30 (15.0) | 23 (14.0) | 7 (19.4)  | 0.571  |
| Seizure (n, %)                             | 1 (0.5)   | 0 (0.0)   | 1 (2.8)   | 0.404  |
| Stroke (n, %)                              | 6 (3.0)   | 4 (2.4)   | 2 (5.6)   | 0.65   |
| Arrhythmia (n, %)                          | 21 (10.5) | 13 (7.9)  | 8 (22.2)  | 0.026  |
| Myocarditis (n, %)                         | 2 (1.0)   | 1 (0.6)   | 1 (2.8)   | 0.796  |
| Heart failure (n, %)                       | 10 (5.0)  | 9 (5.5)   | 1 (2.8)   | 0.8    |
| Acute kidney injury (n, %)                 | 30 (15.0) | 13 (7.9)  | 17 (47.2) | <0.001 |
| Septic shock (n, %)                        | 12 (6.0)  | 1 (0.6)   | 11 (30.6) | <0.001 |
| Acute hepatic injury (n, %)                | 11 (5.5)  | 6 (3.7)   | 5 (13.9)  | 0.042  |
| Acute coronary syndrome (n, %)             | 3 (1.5)   | 1 (0.6)   | 2 (5.6)   | 0.146  |

205 Abbreviations: COPD : Chronic Obstructive Pulmonary Disease

206

## 207 Risk factors for mechanical ventilation

208 Of 200 patients included in the study, we included 145 (72.5%) in the analyses assessing the  
 209 risk factors for mechanical ventilation (MV) (figure 1).

210

### 211 Figure 1. Patient's selection for univariate and multivariate models.

212

213 S1 Table summarizes unadjusted odds of MV at 14 days. Unadjusted odds of MV at 14 days  
 214 were greater in males (odds ratio 2.65, 95% confidence interval 1.15 to 6.72) and in  
 215 overweight patients (odds ratio 2.46, 95% confidence interval 1.11 to 5.81). None of the  
 216 comorbidities increased the unadjusted risk MV at 14 days. Unadjusted odds of MV at 14

217 days were greater for patients presenting with dyspnoea (odds ratio 4.29, 95% confidence  
218 interval 1.86 to 10.85) on admission.

219 NEWS score  $\geq 7$  (odds ratio 9.18, 95% confidence interval 3.66 to 26.55), qSOFA score  $\geq 2$   
220 (odds ratio 6.86, 95% confidence interval 2.68 to 18.47) or a CRB-65 score  $\geq 2$  (odds ratio  
221 4.64, 95% confidence interval 2.07 to 10.65) increased the unadjusted odds of MV.

222 The presence of a radiological infiltrates increased the odds of mechanical ventilation (odds  
223 ratio 11.0, 95% confidence interval 3.14 to 70.45) as did the presence of a bilateral infiltrates  
224 (odds ratio 7.05, 95% confidence interval 2.75 to 21.87). Acute kidney injury on admission  
225 (odds ratio 4.27, 95% confidence interval 1.87 to 9.91), D-dimers of 1000 ng/ml or greater  
226 (odds ratio 3.28, 95% confidence interval 1.37 to 8.25), CRP of 40 mg/l or greater (odds ratio  
227 6.79, 95% confidence interval 1.51 to 18.58) and PCT of 0.5  $\mu\text{g/l}$  or greater (odds ratio 5.99,  
228 95% confidence interval 1.52 to 29.66) increased the unadjusted odds of mechanical  
229 ventilation.

230 Adjusted odds of mechanical ventilation at 14 days were greater in males (odds ratio 3.26,  
231 95% confidence interval 1.21 to 9.8), in patients who presented with a qSOFA score  $\geq 2$  (odds  
232 ratio 6.02, 95% confidence interval 2.09 to 18.82), with bilateral infiltrate (odds ratio 5.75,  
233 95% confidence interval 1.91 to 21.06) or with a CRP of 40 mg/l or greater (odds ratio 4.73,  
234 95% confidence interval 1.51 to 18.58) on admission (Table 6).

235

236 **Table 6. Adjusted risk factors associated with mechanical ventilation at 14 days**

|       | <b>Overall</b> | <b>No<br/>mechanical<br/>ventilation</b> | <b>Mechanical<br/>ventilation</b> | <b>Multivariate<br/>OR [95% CI]</b> | <b>P value</b> |
|-------|----------------|--|-----------------------------------|-------------------------------------|----------------|
| n (%) | 145            | 109                                      | 36                                |                                     |                |

|                                       |           |           |           |                       |       |
|---------------------------------------|-----------|-----------|-----------|-----------------------|-------|
| Male sex (%)                          | 91 (62.3) | 62 (56.9) | 28 (77.8) | 3.26<br>[1.21, 9.80]  | 0.025 |
| qSOFA score $\geq$ 2 (%)              | 23 (16.1) | 9 (8.5)   | 14 (38.9) | 6.02<br>[2.09, 18.82] | 0.001 |
| Bilateral radiological infiltrate (%) | 83 (56.8) | 51 (46.8) | 31 (86.1) | 5.75<br>[1.91, 21.06] | 0.004 |
| C-reactive protein $\geq$ 40 mg/L (%) | 86 (63.7) | 53 (54.1) | 32 (88.9) | 4.73<br>[1.51, 18.58] | 0.013 |

237

238

239

## 240 Discussion

241 Our study identified several risk factors for unfavourable disease progression leading to MV  
242 in patients admitted with COVID-19 in a Swiss university hospital.

243 A quarter of patients for which there were no limitation of care eventually required MV. MV  
244 occurred early during the course of hospitalization and the median duration of MV was  
245 shorter than previously reported [18]. This effect could result from selection bias of patients  
246 with no limitations of care and the limited duration of follow-up.

247 As infection with SARS-CoV-2 may cause an excessive host immune response, leading to  
248 ARDS and death [19]. We would expect biomarkers of inflammation to be associated with  
249 unfavourable outcomes. In this study, CRP  $>$ 40 mg/L on admission was associated with  
250 higher odds of MV, suggesting that an unfavourable course is more frequent in patients with  
251 a severe inflammatory response related to the infection. Several studies have identified an  
252 increased risk of mortality in COVID-19 patients with elevated CRP [17,20]. Other biomarkers  
253 (for example, d-dimers) have also been identified as being associated with an increased risk  
254 of unfavourable outcome, but we did not identify this link in our study [6]. We believe that  
255 CRP is an ubiquitous biomarker whose result could potentially help clinicians assessing the

256 risk of MV in patients with COVID-19. Its use could be easily scaled up due to the availability  
257 of numerous point-of-care test.

258 In our study, we noted an increase in the risk of mechanical ventilation for increasing score  
259 values for NEWS, CRB-65 and qSOFA. qSOFA has been proven a useful predictor of mortality  
260 among patients with suspected infection [13], mainly of bacterial aetiology [21], but also  
261 influenza [22,23]. We opted for including qSOFA in our final multivariate analysis, since it is  
262 widely used by clinicians in our institution, and is quick and easy to apply. A higher  
263 Sequential Organ Failure Assessment score (SOFA) has been previously linked to increased  
264 mortality due to COVID-19 [6]. Data for its calculation are not routinely collected for all  
265 patients outside the ICU, making it a less pragmatic tool to quickly evaluate the risk of MV in  
266 this patient population.

267 We additionally identify male sex as a predictor of unfavourable outcome in patients with  
268 COVID-19, as previously described [24,25]. It is unclear why there is a sex unbalance in the  
269 risk for MV, which could originate in different host response to severe infection [26], notably  
270 SARS-CoV-2.

271 Several factors such as obesity, pregnancy, healthcare worker status, nosocomial acquisition  
272 of SARS-CoV-2 infection, previous ACE inhibitors or ARB II treatment and  
273 immunosuppressive drugs before admission were not associated with severe disease in this  
274 study. Obesity has been described as a risk factor for ICU admission and mortality in patients  
275 with influenza [27,28], we found an association between obesity in COVID-19 patients with  
276 MV in the univariate, but not the multivariate analysis. Comorbidities generally associated  
277 with obesity may contribute in a higher degree to impaired outcomes explaining this finding.

278 We did not identify any relationship between treatment with ECA inhibitors or ARB II and  
279 MV, although it has been suggested their use is associated to better outcomes in patients

280 admitted with SARS-CoV-2 [29]. Age was not risk factor for MV: numerous studies have  
281 linked age to mortality [2,6], but not to the need for MV. This could be due in part to the  
282 limitations of care agreed to in older patients.

283

284 More than half of all admitted patients received a treatment with the intent of being specific  
285 for SARS-CoV-2, although no evidence for their efficacy exists [30]. A key unanswered  
286 question is whether these treatments have an impact on the clinical course of these  
287 patients. However, due to indication bias our study cannot answer this question, which  
288 should be addressed in prospective randomized clinical trials.

289

290 Our study has several limitations to be acknowledged. First, due to its very nature the  
291 sample size is limited, which could lead to observation bias in the analyses, with some  
292 findings likely to evolve over time. The follow-up period was also limited and several  
293 patients were still hospitalised at the time of data analysis. Finally, due to the constantly  
294 evolving nature of the epidemic, the clinical care of patients likely evolved during their  
295 hospitalisation as changes were made to the recommendations for treatments administered  
296 at LUH. The single centre nature of the study limits the generalisability of the results.

297 However, this study gives some valuable insights in the epidemiology and clinical course of  
298 patients admitted in our institution with SARS-CoV-2 infection. We found that male sex,  
299 bilateral SARS-CoV-2 pneumonia, elevated CRP and qSOFA equal or greater to two increased  
300 the risk of mechanical ventilation. The timely identification of these patients could help us  
301 target treatment and better manage the attribution of resources.

302 **Notes**

303

304 **Contributors**

305

306 JR wrote the protocol, participated in data acquisition and validation, performed the data  
307 analysis and drafted the manuscript. MP participated in data acquisition and validation, and  
308 in drafting the manuscript. RB participated in data acquisition and in drafting the  
309 manuscript. PF, JT, FD, BV, EK, LR, DH, MB, CF, KJ and AK participated in data acquisition.  
310 PAB, JLP and OM revised the protocol and the manuscript. LS revised the manuscript. LL took  
311 part in writing the protocol, in analysing the data, and in drafting the manuscript. All authors  
312 contributed to manuscript revision, read and approved the submitted version.

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332 **References**

333 1. World Health Organization: Novel Coronavirus (2019-nCov) Situation Report-22.



- 334 World Health Organization, 2020, February 11, 2020. Available:  
335 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2)  
336 [22-ncov.pdf?sfvrsn=fb6d49b1\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2)
- 337 2. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill  
338 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,  
339 observational study. *Lancet Respir Med.* 2020;0. doi:10.1016/S2213-2600(20)30079-5
- 340 3. World Health Organization: Novel Coronavirus (2019-nCov) Situation Report-22.  
341 World Health Organization, 2020, March 11, 2020. Available:  
342 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10)  
343 [51-covid-19.pdf?sfvrsn=1ba62e57\\_10](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10)
- 344 4. [https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-](https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/covid-19-lagebericht.pdf.download.pdf/COVID-19_Situation_epidemiologique_en_Suisse.pdf)  
345 [ausbrueche-pandemien/2019-nCoV/covid-19-lagebericht.pdf.download.pdf/COVID-](https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/covid-19-lagebericht.pdf.download.pdf/COVID-19_Situation_epidemiologique_en_Suisse.pdf)  
346 [19\\_Situation\\_epidemiologique\\_en\\_Suisse.pdf](https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/covid-19-lagebericht.pdf.download.pdf/COVID-19_Situation_epidemiologique_en_Suisse.pdf), accessed on the 1st April 2020. 2020.
- 347 5. Bai T, Tu S, Wei Y, Xiao L, Jin Y, Zhang L, et al. Clinical and Laboratory Factors  
348 Predicting the Prognosis of Patients with COVID-19: An Analysis of 127 Patients in Wuhan,  
349 China. Rochester, NY: Social Science Research Network; 2020 Feb. Report No.: ID 3546118.  
350 Available: <https://papers.ssrn.com/abstract=3546118>
- 351 6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for  
352 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.  
353 *The Lancet.* 2020;0. doi:10.1016/S0140-6736(20)30566-3
- 354 7. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline  
355 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs  
356 of the Lombardy Region, Italy. *JAMA.* 2020 [cited 9 Apr 2020]. doi:10.1001/jama.2020.5394
- 357 8. Wynants L, Calster BV, Bonten MMJ, Collins GS, Debray TPA, Vos MD, et al. Prediction

358 models for diagnosis and prognosis of covid-19 infection: systematic review and critical  
359 appraisal. *BMJ*. 2020;369. doi:10.1136/bmj.m1328

360 9. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of  
361 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020;25:  
362 2000045. doi:10.2807/1560-7917.ES.2020.25.3.2000045

363 10. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap  
364 consortium: Building an international community of software platform partners. *J Biomed*  
365 *Inform*. 2019;95: 103208. doi:10.1016/j.jbi.2019.103208

366 11. Acute Respiratory Distress Syndrome: The Berlin Definition. *JAMA*. 2012;307: 2526–  
367 2533. doi:10.1001/jama.2012.5669

368 12. AKI Definition. *Kidney Int Suppl*. 2012;2: 19–36. doi:10.1038/kisup.2011.32

369 13. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.  
370 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*.  
371 2016;315: 801–810. doi:10.1001/jama.2016.0287

372 14. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, CAPNETZ Study Group. CRB-65  
373 predicts death from community-acquired pneumonia. *J Intern Med*. 2006;260: 93–101.  
374 doi:10.1111/j.1365-2796.2006.01657.x

375 15. McGinley A, Pearse RM. A national early warning score for acutely ill patients. *BMJ*.  
376 2012;345. doi:10.1136/bmj.e5310

377 16. Yan L, Zhang H-T, Goncalves J, Xiao Y, Wang M, Guo Y, et al. A machine learning-  
378 based model for survival prediction in patients with severe COVID-19 infection. *medRxiv*.  
379 2020; 2020.02.27.20028027. doi:10.1101/2020.02.27.20028027

380 17. Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. A Tool to Early Predict Severe 2019-  
381 Novel Coronavirus Pneumonia (COVID-19): A Multicenter Study using the Risk Nomogram

382 in Wuhan and Guangdong, China. medRxiv. 2020; 2020.03.17.20037515.

383 doi:10.1101/2020.03.17.20037515

384 18. Ling L, So C, Shum HP, Chan PKS, Lai CKC, Kandamby DH, et al. Critically ill patients  
385 with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study. Crit  
386 Care Resusc J Australas Acad Crit Care Med. 2020.

387 19. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-  
388 19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8: 420–  
389 422. doi:10.1016/S2213-2600(20)30076-X

390 20. Lu J, Hu S, Fan R, Liu Z, Yin X, Wang Q, et al. ACP Risk Grade: A Simple Mortality Index  
391 for Patients with Confirmed or Suspected Severe Acute Respiratory Syndrome Coronavirus 2  
392 Disease (COVID-19) During the Early Stage of Outbreak in Wuhan, China. Rochester, NY:  
393 Social Science Research Network; 2020 Feb. Report No.: ID 3543603. Available:  
394 <https://papers.ssrn.com/abstract=3543603>

395 21. Maitra S, Som A, Bhattacharjee S. Accuracy of quick Sequential Organ Failure  
396 Assessment (qSOFA) score and systemic inflammatory response syndrome (SIRS) criteria for  
397 predicting mortality in hospitalized patients with suspected infection: a meta-analysis of  
398 observational studies. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.  
399 2018;24: 1123–1129. doi:10.1016/j.cmi.2018.03.032

400 22. Chang S-H, Yeh C-C, Chen Y-A, Hsu C-C, Chen J-H, Chen W-L, et al. Quick-SOFA score  
401 to predict mortality among geriatric patients with influenza in the emergency department.  
402 Medicine (Baltimore). 2019;98: e15966. doi:10.1097/MD.0000000000015966

403 23. Papadimitriou-Olivgeris M, Gkikopoulos N, Wüst M, Ballif A, Simonin V, Maulini M, et  
404 al. Predictors of mortality of influenza virus infections in a Swiss Hospital during four  
405 influenza seasons: Role of quick sequential organ failure assessment. Eur J Intern Med.

- 406 2020;74: 86–91. doi:10.1016/j.ejim.2019.12.022
- 407 24. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19  
408 and establishment of a host risk score: findings of 487 cases outside Wuhan. *Crit Care*.  
409 2020;24: 108. doi:10.1186/s13054-020-2833-7
- 410 25. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of  
411 COVID-19 from Wuhan: A Retrospective Observational Study. *Am J Respir Crit Care Med*.  
412 2020 [cited 9 Apr 2020]. doi:10.1164/rccm.202003-0543OC
- 413 26. Fish EN. The X-files in immunity: sex-based differences predispose immune  
414 responses. *Nat Rev Immunol*. 2008;8: 737–744. doi:10.1038/nri2394
- 415 27. Fezeu L, Julia C, Henegar A, Bitu J, Hu FB, Grobbee DE, et al. Obesity is associated  
416 with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a  
417 systematic review and meta-analysis. *Obes Rev Off J Int Assoc Study Obes*. 2011;12: 653–  
418 659. doi:10.1111/j.1467-789X.2011.00864.x
- 419 28. Sun Y, Wang Q, Yang G, Lin C, Zhang Y, Yang P. Weight and prognosis for influenza  
420 A(H1N1)pdm09 infection during the pandemic period between 2009 and 2011: a systematic  
421 review of observational studies with meta-analysis. *Infect Dis Lond Engl*. 2016;48: 813–822.  
422 doi:10.1080/23744235.2016.1201721
- 423 29. Yang Guang, Tan Zihu, Zhou Ling, Yang Min, Peng Lang, Liu Jinjin, et al. Effects Of  
424 ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19  
425 Patients With Hypertension: A Single Center Retrospective Study. *Hypertension*. 0.  
426 doi:10.1161/HYPERTENSIONAHA.120.15143
- 427 30. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in  
428 Adults Hospitalized with Severe Covid-19. *N Engl J Med*. 2020. doi:10.1056/NEJMoa2001282
- 429

430 **Supporting information captions**

431 **S1 Table. Unadjusted risk factors associated with mechanical ventilation at 14 days**

